UPDATED LIFETIME SURVIVAL ESTIMATES FOR NIVOLUMAB plus IPILIMUMAB IN PREVIOUSLY UNTREATED ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA (1L ARCC)

被引：0
|
作者：
Qendri, V [1 ]
May, J. [2 ]
Malcolm, B. [2 ]
Ejzykowicz, F. [3 ]
Kurt, M. [3 ]
Cakar, E. [1 ]
Klijn, S. [1 ]
机构：
[1] Pharmerit, Rotterdam, Netherlands
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG5
引用
收藏
页码：S520 / S520
页数：1
相关论文
共 50 条
  • [41] NETWORK META-ANALYSIS OF TREATMENTS IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL-CELL CARCINOMA WITH INTERMEDIATE TO POOR PROGNOSIS
    Laliman, V. A.
    Wang, X.
    Cawston, H.
    Doan, J.
    Dale, P.
    Malcolm, B.
    VALUE IN HEALTH, 2018, 21 : S476 - S476
  • [42] Cost-effectiveness of treatment sequences with front-line nivolumab plus ipilimumab therapy vs immuno-oncology plus tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcinoma
    Ebrahimi, Hedyeh
    Berardi, Andrea
    Smare, Caitlin
    Pavlidou, Eleni
    Guttenplan, Sarah B.
    Eiffert, Sam
    Rosenblatt, Lisa
    Kurt, Murat
    Yin, Xin
    Chehrazi-Raffle, Alexander
    ONCOLOGIST, 2024, 29 : S23 - S24
  • [43] Comparison of long-term survival and cost-effectiveness (CE) of first-line (1L) treatment options in advanced renal cell carcinoma (aRCC) with intermediate or poor (I/P) prognostic risk
    Choueiri, T. K.
    Stwalley, B.
    Huo, S.
    May, J. R.
    Malcolm, B.
    Nickel, K.
    Szabo, N.
    Klijn, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S563 - S564
  • [44] Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi plus Nivo) versus immune checkpoint inhibitors plus tyrosine kinase inhibitors (ICI plus TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC)
    Ostrowski, Micah
    Jo, Yeonjung
    Gebrael, Georges
    Chehade, Chadi Hage
    Narang, Arshit
    Fortuna, Gliceida Galarza
    Thomas, Vinay Mathew
    Chigarira, Beverly
    Anderson, Ethan
    Mazumder, Archisman
    Ozay, Zeynep Irem
    Agarwal, Neeraj
    Maughan, Benjamin L.
    Swami, Umang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] A randomised phase II study of Nivolumab plus Ipilimumab versus Standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)
    Ahrens, M.
    Scheich, S.
    Goekbuget, N.
    Boleti, E.
    Gruenwald, V.
    Escudier, B.
    Goebell, P.
    Gschwend, J.
    Hartmann, A.
    Miller, K.
    Burkholder, I.
    Schmidinger, M.
    Rey, J. P. M.
    Bergmann, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 73 - 73
  • [46] A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast)
    Ahrens, Marit
    Escudier, Bernard
    Boleti, Ekaterini
    Grimm, Marc-Oliver
    Goupir, Marine Gross
    Barthelemy, Pilippe
    Gravis, Gwenaelle
    Bedekes, Jens
    Ivanyi, Philipp
    Panic, Andrej
    Zschaebitz, Stefanie
    Neyrieru, Sylvie
    Mellado, Begona
    Biel, Anika
    Wadell, Tom
    Pablo Maroto, Jose
    Retz, Margitta
    Boegemann, Martin
    Rottey, Sylvie
    Haanen, John
    Oosting, Sjoukje
    Castellano, Daniel
    Hartmann, Arndt
    Bergmann, Lothar
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 226 - 226
  • [47] A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
    Ahrens, Marit
    Escudier, Bernard
    Boleti, Ekaterini
    Grimm, Marc-Oliver
    Gross-Goupil, Marine
    Barthelemy, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] A randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non- clear cell renal cell carcinoma (SUNIFORECAST)
    Bergmann, L.
    Grimm, M. O.
    Boleti, E. B.
    Panic, A.
    Gruellich, C.
    Bedke, J.
    Ahrens, M.
    Lorch, A.
    Negrier, S.
    Ravaud, A.
    Retz, M.
    Boegemann, M.
    Ivanyi, P.
    Siemer, S.
    Bathelemy, P.
    Rottey, S.
    Maroto, P.
    Oosting, S.
    Hartmann, A.
    Escudier, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 285 - 285
  • [49] A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
    Ahrens, Marit
    Escudier, Bernard
    Haanen, John B. A. G.
    Boleti, Ekaterini
    Goupil, Marine Gross
    Grimm, Marc-Oliver
    Negrier, Sylvie
    Barthelemy, Philippe
    Gravis, Gwenaelle
    Ivanyi, Philipp
    Bedke, Jens
    Castellano, Daniel
    Panic, Andrej
    Mellado, Begona
    Maroto-Rey, Pablo
    Rottey, Sylvie
    Zschaebitz, Stefanie
    Deckbar, Dorothee
    Hartmann, Arndt
    Bergmann, Lothar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma
    Ali, Sahra
    Camarero, Jorge
    van Hennik, Paula
    Bolstad, Bjorg
    Gronvold, Maja Sommerfelt
    Syvertsen, Christian
    Strom, Bjorn Oddvar
    Okvist, Mats
    Josephson, Filip
    Keller-Stanislawski, Brigitte
    Zafiropoulos, Nikolaos
    Pean, Elias
    Bergh, Jonas
    Dias, Silvy da Rocha
    Pignatti, Franscesco
    ESMO OPEN, 2020, 5 (06)
12345